【摘要】 目的 观察我院2020—2022年鲍曼不动杆菌院内感染分布情况及耐药性情况，探究有效应对鲍曼不动杆菌院内感染的方法。方法 回顾性分析济南市长清区人民医院2020年1月至2022年12月鲍曼不动杆菌院内感染分布情况并对获取样本进行药敏试验，观察不同抗菌药物药敏情况。结果 共纳入2020年1月至2022年12月我院普外科住院患者1 000例作为研究对象，出现院内鲍曼不动杆菌感染情况共计80例。2020年1～12月共计出现院内鲍曼不动杆菌感染18例；2021年1～12月共计出现院内鲍曼不动杆菌感染22例；2022年1～12月共计出现院内鲍曼不动杆菌感染40例，院内鲍曼不动杆菌感染发生率有升高趋势，差异有统计学意义（P <0.05）。2020年药敏试验结果显示替加环素、妥布霉素敏感性（100%）较高；除替加环素、妥布霉素、米诺环素外，其他抗生素均出现不同程度耐药性，其中阿米卡星、环丙沙星、甲氧苄氨嘧啶/磺胺、哌拉西林/他唑巴坦、庆大霉素、头孢曲松、头孢他啶药物耐药性较高；2021年药敏试验结果显示多粘菌素B、米诺环素、替加环素敏感性（100%）较高；除多粘菌素B、米诺环素、替加环素、左氧氟沙星外，其他抗生素均出现不同程度耐药性，其中氨曲南、氯霉素耐药性较高；2022年药敏试验结果显示多粘菌素B、米诺环素、妥布霉素敏感性（100%）较高；除多粘菌素B、米诺环素、妥布霉素外，其他参与研究抗生素均出现不同程度耐药性，其中阿米卡星、氨苄西林/舒巴坦、呋喃妥因、环丙沙星、氯霉素、美罗培南、哌拉西林/他唑巴坦、庆大霉素、替卡西林/棒酸、头孢吡肟、头孢曲松、头孢他啶、亚胺培南、左氧氟沙星耐药性较高。结论 2020-2022年鲍曼不动杆菌院内感染调查结果显示，每年均有感染情况出现，有逐年升高趋势，药敏试验结果显示此类感染对大多数抗生素存在耐药性，其中替加环素、妥布霉素、米诺环素药物药敏性较为理想，可应用于鲍曼不动杆菌院内感染的治疗。更多还原

【Abstract】 Objective To observe the distribution and drug resistance of Acinetobacter baumannii infection in our hospital from 2020 to 2022,and explore effective methods for treating Acinetobacter baumannii in hospital infection. Methods A retrospective analysis was conducted on the distribution of Acinetobacter baumannii infection in Changqing District People’s Hospital of Jinan City from January 2020 to December 2022. Drug sensitivity tests were conducted on the collected samples to observe the drug sensitivity of different antibiotics. Results From January 2020 to December 2022, a total of 80 cases of hospital acquired Acinetobacter baumannii infection occurred. From January to December 2020, a total of 18 cases of hospital acquired Acinetobacter baumannii infection occurred; From January to December 2021, a total of 22 cases of hospital acquired Acinetobacter baumannii infection occurred; From January to December 2022, a total of 40 cases of hospital acquired Acinetobacter baumannii infection occurred, and the incidence of hospital acquired Acinetobacter baumannii infection showed an increasing trend, with a statistically significant difference(P<0.05). The results of drug sensitivity test in 2020 showed that tigecycline and tobramycin were highly sensitive(100%); Except for tigecycline, tobramycin and minocycline, other antibiotics are resistant to varying degrees, of which amikacin,ciprofloxacin, trimethoprim/sulfa, piperacillin/tazobactam, gentamicin, ceftriaxone and ceftazidime are highly resistant; The drug sensitivity test in 2021 showed that polymyxin B, minocycline and tigecycline were highly sensitive(100%); Except for polymyxin B, minocycline,tigecycline and levofloxacin, other antibiotics have different degrees of resistance, of which aztreonam and chloramphenicol have higher resistance; The drug sensitivity test results in 2022 showed that polymyxin B, minocycline, and tobramycin were highly sensitive(100%); In addition to polymyxin B, minocycline and tobramycin, other antibiotics involved in the study showed different degrees of resistance, among which amikacin, ampicillin/sulbactam, furantoin, ciprofloxacin, chloramphenicol, meropenem, piperacillin/tazobactam, gentamicin, ticarcillin/clavulanic acid, cefepime, ceftriaxone, ceftazidime, imipenem and levofloxacin were highly resistant. Conclusions The investigation results of Acinetobacter baumannii nosocomial infection in 2020-2022 showed that the infection occurred every year, with an increasing trend year by year. The drug sensitivity test results showed that this kind of infection was resistant to most antibiotics, among which tigecycline,tobramycin, and minocycline had relatively ideal drug sensitivity, and they can be used for clinical treatment of Acinetobacter baumannii nosocomial infection.更多还原